After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

Hims and other telehealth firms make finasteride easy to get and don’t have to disclose side effects in ads.

But their days are likely numbered. During Sunday’s Super Bowl, Hims & Hers Health—a telehealth provider known for its provocative ads promoting erectile dysfunction and hair-loss treatments ...

The minute-long ad from telehealth company Hims & Hers shows imagery including a scale, food including pies and cheeseburgers, and a refrigerator full of vials of Hims & Hers-labeled medications ...

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site. The ad also hit a nerve with the pharma industry, lawmakers and some industry groups. The ad ...

Hims & Hers Health has undeniably captured market attention and investor enthusiasm, fueled by a successful Super Bowl ad campaign and its strategic entry into the high-demand GLP-1 weight loss ...

Hims & Hers saw a massive YTD surge, but FDA news led to a pullback. Find out why HIMS stock is still undervalued and why ...

Telehealth stock Hims & Hers (HIMS) spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper GLP-1 weight-loss drugs sparked controversy. The ad criticized the ...

The “Check before you inject” ad specifically calls out compounded medications, which is the type that Hims & Hers manufactures and is not FDA approved. Novo Nordisk blasted its telehealth ...

Although the telemedicine company displayed blistering growth and issued robust guidance, shares of Hims & Hers (NYSE: HIMS) ...

The reaction: Last week, Senators Richard Durbin, a Democrat, and Roger Marshall, a Republican, criticized Hims & Hers' ad, writing in a letter to the FDA that the company didn’t include the ...